Swiss can­cer vac­cine biotech Nous­com rais­es $72M Se­ries C for PhII tri­als

Basel-based biotech Nous­com has raised €67.5 mil­lion ($72.2 mil­lion) to bankroll its can­cer vac­cines as the eight-year-old com­pa­ny looks to cap­i­tal­ize on mo­men­tum in the field.

The Se­ries C marks the biotech’s first ven­ture in­vest­ment in about six years; it last raised a $49 mil­lion Se­ries B in late 2017.

“We’ve been care­ful not to over-com­mit our­selves on spend­ing as we’ve gone and we’re very da­ta-led, not hope-led, on these things,” op­er­at­ing and busi­ness chief Richard Davis told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER